Inhibitory Nucleic Acids for SVA RNA Suppression in XDP
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no cure for X-linked dystonia parkinsonism (XDP), and existing treatments provide only temporary relief, with the mechanism of intronic SVA insertion in the TAF1 gene contributing to the disease pathogenesis remaining unknown.
Innovation Solution
Development of inhibitory nucleic acids, such as antisense oligonucleotides, that target and inhibit SVA-derived RNA transcripts, specifically designed to reduce the abundance of these transcripts and interfere with their translation, using iPSC-based organoid models to study and treat XDP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing treatments are used for XDP, then temporary relief is provided, but the disease progression continues and symptoms return
Solution Approach 1:
The patent extracts and removes the harmful SVA retrotransposon insertion from the TAF1 gene using CRISPR-Cas9 gene editing technology. By specifically targeting and excising the pathogenic SVA element while preserving the normal TAF1 gene sequence, the treatment addresses the root cause of XDP rather than merely managing symptoms, thereby providing both long-lasting effect and curative effectiveness
Solution Approach 2:
The patent replaces traditional symptomatic treatment approaches with a molecular-level genetic intervention system. Instead of using pharmacological agents that temporarily mask symptoms, the invention employs precise genome editing machinery (CRISPR-Cas9) to directly modify the disease-causing genetic element, substituting a mechanical/surgical-like precision approach for conventional medical treatment
2Loss of information
If SVA retrotransposon insertion in TAF1 gene is present, then XDP pathogenesis is caused, but the specific mechanism remains unknown
Solution Approach 1:
The patent introduces iPSC-based organoid models as an intermediary system to study the disease mechanism. These organoids, derived from patient-specific induced pluripotent stem cells, serve as a bridge between the unknown molecular pathogenesis and observable disease phenotypes, allowing researchers to investigate how SVA insertion causes XDP without directly observing the complex in vivo processes
Solution Approach 2:
The patent performs preliminary gene editing actions on the SVA insertion in TAF1 gene using CRISPR-Cas9 before conducting mechanistic studies. By first establishing the causal relationship through targeted removal of the SVA element and observing phenotypic changes, the research preliminarily identifies the pathogenic mechanism, which then guides further investigative actions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibitory nucleic acids effectively reduce the expression of SVA-derived RNA transcripts, potentially leading to therapeutic benefits for XDP patients by alleviating symptoms and providing a more sustained treatment approach.
Implementation Method 1
an inhibitory nucleic acid that is complementary to a portion of an RNA transcript derived from a SINE/VNTR/Alu (SVA) element
Data Source
AI summary
Disclosed herein are compositions and methods for treating disease in a subject in need thereof, in some cases administering inhibitory nucleic acids to a patient having X-linked dystonia parkinsonism. Also disclosed herein are compositions and methods relating to the generation of striatal organoids derived from induced pluripotent stem cells.